Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.